Company Overview

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule and antibody-based therapies for cancer, with an emphasis on immuno-oncology. The company’s strategy centers on targeting key regulators of immune cell function to enhance anti-tumor immune responses, particularly in areas of high unmet medical need. Corvus does not generate product revenue and currently derives no income from commercialized products, relying instead on capital markets to fund research and development.

Founded in 2014, Corvus Pharmaceuticals has evolved from an early-stage immunotherapy research company into a more focused clinical organization advancing proprietary drug candidates through mid-stage clinical trials. Its pipeline development has been shaped by advances in immune checkpoint biology and tumor microenvironment modulation, positioning the company within the highly competitive oncology drug development landscape.

Business Operations

Corvus operates as a single reportable segment focused on research and development, with substantially all activities dedicated to advancing its oncology pipeline. Its primary assets include CPI-818, a selective oral inhibitor of interleukin-2-inducible T-cell kinase (ITK), and CPI-006 (mupadolimab), a monoclonal antibody targeting CD73 designed to activate B cells and stimulate anti-tumor immunity. Earlier programs, including ciforadenant, an adenosine A2A receptor antagonist, contributed foundational scientific insights but are no longer central to the company’s lead strategy.

The company conducts clinical development primarily through outsourced clinical research organizations and maintains internal capabilities in drug discovery, translational science, and regulatory strategy. Corvus has historically engaged in selective collaborations with academic institutions and research partners but does not currently report material revenue-generating partnerships or joint ventures.

Strategic Position & Investments

Corvus’s strategic direction is focused on advancing CPI-818 in T-cell lymphomas and other immune-driven malignancies, leveraging its differentiated mechanism targeting ITK to potentially improve efficacy while reducing off-target toxicity. The company prioritizes disciplined capital allocation toward programs with biomarker-driven patient selection and clear clinical endpoints.

Investment activity has largely been internal, centered on funding clinical trials and supporting intellectual property development. Corvus does not maintain a diversified subsidiary or portfolio company structure; instead, its value proposition is concentrated in its wholly owned drug candidates. The company remains engaged in emerging immunotherapy approaches that modulate immune cell signaling rather than conventional checkpoint inhibition.

Geographic Footprint

Corvus Pharmaceuticals is headquartered in South San Francisco, California, within the United States, a major global hub for biotechnology innovation. Its operational footprint is primarily domestic, with corporate management, research oversight, and strategic planning conducted from its U.S. headquarters.

Internationally, the company’s presence is indirect, primarily through global clinical trial sites and relationships with international contract research organizations. While Corvus does not operate foreign offices, its clinical development programs involve patient enrollment across multiple regions, giving it limited but meaningful international exposure.

Leadership & Governance

Corvus is led by an executive team with extensive experience in oncology drug development, biotechnology entrepreneurship, and clinical research. Leadership emphasizes scientific rigor, capital efficiency, and focused clinical execution as core elements of the company’s governance philosophy.

Key executives include:

• Richard A. Miller, M.D. – President and Chief Executive Officer
• Leen Kawas – Chief Financial Officer
• Sean F. O’Day, M.D. – Chief Medical Officer

Some executive role details have shown variation across public disclosures; where discrepancies exist, data is inconclusive based on available public sources.